(Q51472027)

5 April 2018

title

Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. (English)

1 reference

5 April 2018

1 reference

1

1 reference

5 April 2018

Sverre E. Kjeldsen

7

object named as

Kjeldsen SE

1 reference

5 April 2018

Olsen MH

2

1 reference

5 April 2018

Wachtell K

3

1 reference

5 April 2018

Hille DA

4

1 reference

5 April 2018

Dahlöf B

5

1 reference

5 April 2018

Ibsen H

6

1 reference

5 April 2018

Lyle PA

8

1 reference

5 April 2018

Devereux RB

9

1 reference

5 April 2018

publication date

3 May 2007

1 reference

5 April 2018

Journal of Human Hypertension

published in

1 reference

5 April 2018

volume

21

1 reference

5 April 2018

page(s)

625-632

1 reference

5 April 2018

issue

8

1 reference

5 April 2018

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1002203

exact match

0 references

cites work

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

The deadly quartet and the insulin resistance syndrome: an historical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Prognostic value of the metabolic syndrome in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

The metabolic syndrome: a call to action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

The metabolic syndrome: more than the sum of its parts?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Metabolic Syndrome Is Associated With Aortic Stiffness in Untreated Essential Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Carotid artery remodeling in middle-aged women with the metabolic syndrome (from the "Progetto ATENA" study).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Influence of metabolic syndrome on hypertension-related target organ damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Dyslipidemic hypertension: distinctive features and cardiovascular risk in a prospective population-based study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Metabolic syndrome and risk of cardiovascular events after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

NHLBI family blood pressure program: methodology and recruitment in the HyperGEN network. Hypertension genetic epidemiology network

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

An evaluation of the metabolic syndrome in the HyperGEN study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Is high pulse pressure a marker of preclinical cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

State of the heart in the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Prevalence of the metabolic syndrome among Italian adults according to ATP III definition.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002203

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1002203

1 reference

5 April 2018

PubMed ID

17476291

1 reference

5 April 2018